Michael B. Brenner, MD, addresses exciting advances in basic science in rheumatology, including insights into inflammation in osteoarthritis, the adult-onset autoinflammatory syndrome VEXAS and more.
Search results for: hospital
Meet New ACR President Kenneth G. Saag, MD, MSc
Kenneth G. Saag, MD, MSc, is a nationally recognized expert & researcher in the epidemiology of gout, osteoporosis & rheumatoid arthritis. Dr. Saag brings a penchant for problem solving & a strong belief in the power of collaboration to his newest role in the College as the 85th ACR president.
North Carolina Rheumatology Association Looks to the Future
With more than 100 members, including rheumatologists, physician assistants and nurse practitioners, the NCRA is a dynamic, member-owned organization.
The Art & Science of Imaging the Pediatric Sacroiliac Joint
Additional training may be needed on the appearance of the maturing sacroiliac (SI) joint on MRI. In a recent study, researchers found local radiologists may mistake normal physiologic changes of a maturing SI joint as sacroiliitis in pediatric patients.
ACR Convergence 2021 Offers Great Networking Opportunities
Through sessions and Community Hubs, attendees of ACR Convergence 2021 have multiple opportunities to connect with other rheumatology professionals. Here are some helpful tips from panelists.
Considerations for Prescribing Avacopan for ANCA-Associated Vasculitis
In early October, the FDA approved avacopan to treat anti-neutrophil cytoplasmic antibody associated vasculitis. Here are insights into the treatment’s risks and considerations.
The Clinical Value of Antiphospholipid Antibodies in Patients with COVID-19
Gendron et al. undertook this study to investigate the prevalence and prognostic value of conventional and nonconventional antiphospholipid antibodies in patients with COVID-19.
TNF Inhibitors & Pregnancy: How Well Does the Treatment Guidance Work?
Ghalandari et al. sought to validate the guidance outlined by EULAR for the use of anti-rheumatic drugs during pregnancy, finding that following its guidance for tumor necrosis factor inhibitors led to no or low concentrations of these agents in cord blood.
FDA Approves Cyltezo, an Interchangeable Biosimilar to Humira
On Oct. 15, the U.S. Food & Drug Administration (FDA) approved the first interchangeable biosimilar product to treat certain inflammatory diseases. Cyltezo (adalimumab-adbm), originally approved in August 2017, is both biosimilar to and interchangeable with (i.e, may be substituted for) its reference product Humira (adalimumab) for Cyltezo’s approved uses. Cyltezo is the second interchangeable biosimilar…
Trial Pits Upadacitinib vs. Adalimumab for Psoriatic Arthritis
As treatments for psoriatic arthritis (PsA) emerge, a clinical trial comparing the Janus kinase (JAK) inhibitor upadacitinib and the tumor necrosis factor (TNF) inhibitor adalimumab provided some new insights. Published earlier this year in The New England Journal of Medicine, the SELECT-PsA 1, double-blind, phase 3 trial found that a 30 mg dose of upadacitinib…
- « Previous Page
- 1
- …
- 56
- 57
- 58
- 59
- 60
- …
- 319
- Next Page »